# Top
#### kind: StartAI
#### area: Bio
#### stance: 
## Sections
### Cash
#### cash_trend: upward
#### cash: 
#### cash_available: 100
### Coolness
#### cool: B
#### cool_why: 
#### cool_mission: 
#### cool_balance: 
#### cool_dan: 
#### mission: 
To bring better drugs to patients faster by leveraging machine learning and data at scale to decode the complexities of biology and unlock transformative new medicines ￼.
### Deep Learning Projects (DLP)
#### dlp: B
#### dlproj1: 
Machine learning for NASH drug discovery: Collaboration with Gilead using insitro’s ML-driven platform (ISH) to create in vitro disease models and identify therapeutic targets for NASH ￼.
#### dlproj2: 
AI-driven neuroscience (ALS/FTD): Five-year partnership with Bristol Myers Squibb applying insitro’s platform to iPSC-derived models for ALS and FTD, to discover novel targets and design ML-based therapeutics ￼.
#### dlproj3: 
Metabolic disease collaboration: Multi-agreement partnership with Eli Lilly leveraging insitro’s AI platform to identify targets for metabolic disorders (e.g., MASLD) and develop siRNA and antibody therapies ￼.
### Job Postings
#### job: 
#### job_why: 
#### job_bay: (Bay Area roles are hybrid; remote option available for many insitro roles)
#### job_remote: Staff Machine Learning Scientist, Integrative Phenotyping – Google search
### Toxicity
## Misc Fields
#### bam:
#### dlp_:
### recent_funding: Raised $400M Series C in Mar 2021 ￼
